MTOR and cancer: In our study, rhPGRN-treated HepG2 cells showed enhanced phosphorylation of mTORC1 downstream targets p70S6K, 4E-BP1 and mTORC2-dependent Akt Ser473, which provides the first evidence for PGRN-stimulated activation of mTOR signaling in human cancer cells.